Search
A groundbreaking study has revealed that elranatamab, a BCMA-targeted CAR-T cell therapy, demonstrates robust tolerability and notable clinical efficacy in the treatment of progressive multiple sclerosis (MS). The clinical trial centered on three individuals diagnosed with severe progressive MS, and subsequent to treatment, these patients experienced marked improvements in their physical functions. Notably, cerebrospinal fluid biomarkers became negative, and imaging assessments confirmed disease stabilization. Safety evaluations indicated that patients encountered only mild adverse effects, with no reports of severe neurotoxic reactions. These promising findings underscore the broad therapeutic potential of elranatamab in the management of multiple sclerosis.
-
C114 Communication Network -
Communication Home
